8-K: Zymeworks Appoints Oleg Nodelman to Board of Directors

Zymeworks Inc. appoints Oleg Nodelman, Founder and Portfolio Manager of EcoR1 Capital, LLC, to its board of directors, effective February 17, 2025.

Summary

• Zymeworks Inc. has appointed Oleg Nodelman to its board of directors, effective February 17, 2025.
• Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC.
• He was appointed as a Class II director with a term expiring at the company's 2026 annual general meeting of stockholders and named to the Nominating Committee.
• EcoR1 previously purchased pre-funded warrants to acquire 5,086,521 shares of Zymeworks' common stock for approximately $50 million.
• The purchase price for the pre-funded warrants was $9.8299 per share.
• Mr. Nodelman has waived his entitlement to cash and equity compensation otherwise payable to him pursuant to the company's non-employee director compensation policy.
• Scott Platshon, also from EcoR1, was appointed to the Compensation Committee of the Board, effective February 17, 2025.
• Zymeworks is a clinical-stage biotechnology company focused on developing novel biotherapeutics for difficult-to-treat diseases.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of a well-regarded investor representative to the board, the ongoing board renewal process, and the company's commitment to developing innovative therapies. EcoR1's investment and alignment with Zymeworks' mission further contribute to the positive outlook.

Positives

• The appointment of Oleg Nodelman brings significant biotech investment and business development experience to the Zymeworks board.
• EcoR1's substantial investment in Zymeworks demonstrates confidence in the company's mission and future prospects.
• The board renewal process is bringing fresh perspectives and expertise to the company's leadership.
• Zymeworks has a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need.
• Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric technology.
• The U.S. FDA granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC).

Risks

• The forward-looking statements in the press release are subject to various risks and uncertainties, including the potential failure of product candidates, regulatory delays, and market conditions.
• Zymeworks may not achieve milestones or receive additional payments under its collaborations.
• Clinical trials and any future clinical trials may not demonstrate safety and efficacy of any of Zymeworks or its collaborators product candidates.
• Zymeworks may be unable to maintain or enter into new partnerships or strategic collaborations.

Future Outlook

Zymeworks plans to continue advancing its pipeline of product candidates, including ZW171, ZW191, ZW220 and ZW251, and to develop transformative therapies for patients.

Management Comments

• 'As the largest current stockholder of Zymeworks, we at EcoR1 are aligned with the company's mission and committed to its future success for patients, employees and stockholders,' said Oleg Nodelman.
• 'I look forward to working closely with the board of directors and talented employees as we execute on our long-term strategy to realize the full potential of Zymeworks,' said Oleg Nodelman.
• 'We are pleased to welcome Oleg to Zymeworks board of directors and believe his significant biotech sector experience will support our mission to develop transformative therapies for patients, while delivering lasting value to all our stockholders,' said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
• 'Oleg's deep industry knowledge and experience make him an exceptional addition to the board of directors,' said Sue Mahony, Ph.D., MBA, lead independent director of Zymeworks.
• 'As part of our board renewal process, we are confident that Oleg's strategic insights will help drive the company's growth and reinforce our dedication to addressing critical medical challenges for patients,' said Sue Mahony, Ph.D., MBA, lead independent director of Zymeworks.

Industry Context

The appointment of a representative from a major investor like EcoR1 to the board is a common practice in the biotech industry, reflecting the investor's commitment and providing valuable insights into the company's strategy and operations. This move aligns with the trend of biotech companies seeking expertise from investment firms with deep industry knowledge.

Comparison to Industry Standards

• The board appointment of a major investor representative is a common practice in the biotech industry, similar to instances like venBio's representation on the board of various portfolio companies.
• EcoR1's investment size and board representation are comparable to other biotech-focused investment firms like OrbiMed or RA Capital Management, which often take board seats in their portfolio companies.
• Zymeworks' board renewal process is in line with industry best practices, as companies like Amgen and Biogen have also undergone similar processes to refresh their boards with diverse expertise.

Management Changes

Related Party Transactions

• EcoR1's purchase of pre-funded warrants and the associated registration rights agreement constitute related party transactions.

Stakeholder Impact

• Shareholders may view the appointment of Oleg Nodelman positively, given EcoR1's investment and expertise in the biotech sector.
• Employees may benefit from Mr. Nodelman's insights and contributions to the company's strategy.
• Patients may benefit from the company's continued development of innovative therapies.

Next Steps

• Mr. Nodelman will participate in board meetings and contribute to the company's strategic decision-making.
• Zymeworks will continue to advance its clinical programs and seek regulatory approvals for its product candidates.
• ZW220 and ZW251 investigational new drug applications are planned for 2025.

Key Dates

Keywords

Zymeworks, Oleg Nodelman, EcoR1 Capital, Board of Directors, Appointment, Biotechnology, Zanidatamab, Investment, Director, Biotherapeutics